Xention, Ltd., a Cambridge, UK-based biopharmaceutical company specializing in the discovery and development of ion channel-modulating drugs, has closed an £8m series D financing.
The round was led by new investor Seroba-Kernel Life Sciences Ltd, with participation from existing investors Forbion Capital Partners, Crédit Agricole Private Equity, MVM and BTG International.
The company intends to advance to clinical proof of concept its novel drugs for the treatment of atrial fibrillation, a common cardiac rhythm disturbance. Xention also has drug candidates in overactive bladder and autoimmune disease.
In conjunction with the funding, Graham Fagg of Seroba-Kernel will join the company’s board of directors.